Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.48 |
| ▸ | MAPT | P10636 | 11/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20242252 | 0.91 | HTR6 (0.50) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242507 | 0.90 | HTR6 (0.47) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242149 | 0.87 | HTR6 (0.47) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242467 | 0.86 | HTR6 (0.64) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242363 | 0.86 | HTR6 (0.46) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL21378916 | 0.84 | HTR6 (0.50) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242472 | 0.84 | HTR6 (0.47) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20242670 | 0.83 | HTR6 (0.57) | HTR6MAPTMAPK1SMN1; SMN2HPGD | |
| SCHEMBL20242536 | 0.83 | HTR6 (0.49) | HTR6MAPTALDH1A1KMT2ANPSR1 | |
| SCHEMBL20241883 | 0.83 | HTR6 (0.48) | HTR6MAPTALDH1A1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | MICROBIOTIX, INC. (US) | 2022-10-04 | — | — | US | claimed |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2019-09-26 | — | — | US | claimed |
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | MICROBIOTIX, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| EP-3548034-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | Microbiotix, Inc. (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2019-09-26 | — | — | US | disclosed |
| WO-2018106667-A1 | BROAD-SPECTRUM INHIBITORS OF FILOVIRUSES | MICROBIOTIX, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11459308-B2 | Broad spectrum inhibitors of filoviruses | NPC1L1, NPC1, GBA1 | HTR6 4498/4885MAPT 3677/4885ALDH1A1 3771/4885 |
| US-20190292165-A1 | BROAD SPECTRUM INHIBITORS OF FILOVIRUSES | NPC1L1, NPC1, GBA1 | HTR6 4498/4885MAPT 3677/4885ALDH1A1 3771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.